LLM 2021 | BTKi combinations for CLL
Neil Kay, MD, Mayo Clinic, Rochester, MN, discusses combination treatments for chronic lymphocytic leukemia (CLL). Increasing data shows that combinations of Bruton’s tyrosine kinase inhibitors (BTKi) with anti-CD20 antibodies or the combination of venetoclax with a BTKi are promising. High overall responses are achieved, as with single-agent BTKi, but with increasing levels of complete response (CR) and undetectable minimal residual disease (MRD). Prof. Kay highlights the Phase III trial (E1912; NCT02048813) that reported that the combination of ibrutinib with rituximab was effective with enhanced progression-free survival (PFS) and overall survival (OS) compared with the prior gold-standard fludarabine, cyclophosphamide, and rituximab in patients with previously untreated CLL. Overall, data suggest that BTKi combinations are going to be highly effective for CLL patients. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.
Disclosures
Advisory Board for: Abbvie, Astra Zeneca, Beigene, Behring, Cytomx Therapy, Dava Oncology, Janssen, Juno Theraputics, Oncotracker, Pharmacyclics and Targeted Oncology. DSMC (Data Safety Monitoring Committee) for: Agios Pharm, AstraZeneca, BMS –Celgene, Cytomx Therapeutics, Janssen, Morpho-sys, Rigel. Research funding from: Abbvie, Acerta Pharma, Bristol Meyer Squib, Celgene, Genentech, MEI Pharma, Pharmacyclics, Sunesis, TG Therapeutics, Tolero Pharmaceuticals.
